In This Issue

► Plenary Speaker Announcements
   See who’s leading this year’s plenary sessions!

► Key Topics. Top Speakers.
   Explore the meeting’s carefully crafted educational program.
Are you getting the most out of your Rb-82 Generator?

The RUBY-FILL® Rubidium 82 Generator is clinically proven to deliver industry-leading efficiency with reliable consistency and dosing flexibility1-3

RUBY-FILL® has been proven to

Consistently deliver expected yield with nearly 100% accuracy
• In a recent study comparing currently available generators, RUBY-FILL® showed industry-leading efficiency3

Deliver highly accurate patient doses
• Over the life of the generator, the deviation of delivered dose vs. requested dose approached 0%3

Provide clinical flexibility
• RUBY-FILL® provides a long shelf life and flexible, patient-specific dosing1

Seem unbelievable?
Visit Jubilant Radiopharma at the SNMMI Virtual Meeting Online July 11-13 to see for yourself

Indication for Use: RUBY-FILL is a closed system used to produce rubidium (Rb-82) chloride injection for intravenous use. Rubidium (Rb-82) chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

New Important Safety Information April 2019
Please note changes in Boxed Warning, Dosage and Administration, Directions for Eluting Rubidium Rb 82 Chloride Injection (2.5), Contraindications (4), Warnings and Precautions, High Level Radiation Exposure with Use of Incorrect Eluent (5.1).

The risk information provided here is not comprehensive. Please visit RUBY-FILL.com for full Prescribing Information including BOXED WARNING.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-1088.

References:
1. RUBY-FILL [package insert]. Kirkland, Quebec, Canada: Jubilant DraxImage Inc; April 2019.
A Re-Imagined Experience: Virtually Connecting You with Your Colleagues from Around the World!

The SNMMI 2020 Annual Meeting - Virtual Edition—Saturday, July 11 through Tuesday, July 14—gives you the unique opportunity to attend live continuing education sessions, review hundreds of scientific abstracts, connect with suppliers in the exhibit hall, and network with other attendees—all in an exciting, interactive virtual environment.

Best of all, the easy-to-use platform will mimic the dynamics of an in-person event, making it easy to navigate around and take full advantage of all the features the meeting has to offer. All you will need is an internet connection!

The SNMMI Annual Meeting - Virtual Edition connects you with:

☑️ An Immersive Virtual Learning Experience
More than 25 one-hour sessions will be available over 3.5 days, featuring live chat functionality during live broadcasts of the presentations. Miss a session? Each session will be available for on-demand viewing following its live broadcast.

☑️ Leading Research in the New Science Pavilion
View abstract presentations and posters of the profession’s latest research, including recorded oral presentations from the authors. You will also be able to ask the authors questions by emailing them while visiting their poster/abstract.

☑️ Industry Suppliers in an Interactive Exhibit Hall
Visit customized virtual booths from top suppliers and learn more about their products/services through videos and downloadable presentations. Plus, connect through one-on-one meetings with exhibit personnel while visiting their booth.

☑️ Innovative Networking Opportunities
Interact with fellow attendees through one-on-one and group chat, and during great networking events, including Molecular Hub Meet-Ups, Saturday night Movie Viewing Party, the Presidents’ Town Hall and Reception, and more.

☑️ No Registration Fee for SNMMI Members
Although registration is required, the Annual Meeting - Virtual Edition is free for SNMMI members. Non-members may either join SNMMI to attend at no cost or pay a modest fee. Please note: registration closes at 11:59 pm ET on Thursday, July 9.

WWW.SNMMI.ORG/VIRTUALPREVIEW

THANK YOU TO OUR TITLE SPONSOR

We would like to recognize our title sponsor, Advanced Accelerator Applications, a Novartis Company, for their generous support of the SNMMI 2020 Annual Meeting - Virtual Edition.

Earn up to 24 continuing education credits.
# PLENARY SESSIONS

The **SNMMI 2020 Annual Meeting** – Virtual Edition will continue to feature the anticipated Plenary Sessions. These sessions feature addresses by key luminaries, highlight significant awards and accomplishments, the installation of the new SNMMI president, a synopsis of research during the Annual Meeting, announcement of the Image of the Year, and more!

**Sunday, July 12** ▶ 10:00–11:00 am  
“SNMMI President’s Address”  
Vasken Dilsizian, MD

**Monday, July 13** ▶ 10:00–11:00 am  
“SNMMI Year in Review”  
Vasken Dilsizian, MD

**Sunday, July 12** ▶ 10:00–11:00 am  
Henry N. Wagner, Jr., MD, Lectureship  
“Molecular Imaging in Cardiovascular Medicine: Setting Tiny Targets for Greater Goals”  
Jagat Narula, MD, PhD, MACC

**Tuesday, July 14** ▶ 10:00–11:00 am  
SNMMI-TS Year in Review  
Mark Crosthwaite, CNMT, FSNMMI-TS

**Monday, July 13** ▶ 10:00–11:00 am  
Benedict Cassen, MD, Lectureship  
“Imaging in 2020 and Beyond: Expect the Unexpected”  
Peter Conti, MD, PhD

**Tuesday, July 14** ▶ 6:15–8:00 pm  
Henry N. Wagner, Jr., MD, Highlights Lecture: Cardiology  
Mehran Sadeghi, MD

**Tuesday, July 14** ▶ 6:15–8:00 pm  
Henry N. Wagner, Jr., MD, Highlights Lecture: General Nuclear Medicine  
Heather Jacene, MD

**Tuesday, July 14** ▶ 6:15–8:00 pm  
Henry N. Wagner, Jr., MD, Highlights Lecture: Neuroscience  
Julie Price, PhD

**Tuesday, July 14** ▶ 6:15–8:00 pm  
Henry N. Wagner, Jr., MD, Highlights Lecture: Oncology  
Andrew Scott, MD, FRACP, DDU, FAICD, FAHMS, FAANMS

[www.snmmi.org/AMPlenary](http://www.snmmi.org/AMPlenary)
<table>
<thead>
<tr>
<th>Time</th>
<th>Saturday</th>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30–2:30 pm</td>
<td>Molecular Hub – Virtual Meeting Overview</td>
<td>9:00–10:00 am</td>
<td>Molecular Hub – Council &amp; Center Leadership</td>
<td>9:00–10:00 am</td>
</tr>
<tr>
<td>2:30–3:30 pm</td>
<td>Opening/Welcome</td>
<td>10:00–11:00 am</td>
<td>SNMMI President’s Address/ Wagner Lecture</td>
<td>SNMMI-TS Plenary Session</td>
</tr>
<tr>
<td>3:30–4:30 pm</td>
<td>Non-Invasive Evaluation of CAD in 2020</td>
<td>11:00–11:15 am</td>
<td>Break</td>
<td>11:00–11:15 am</td>
</tr>
<tr>
<td>4:30–5:00 pm</td>
<td>Visit the Exhibit Hall</td>
<td>11:15 am–12:15 pm</td>
<td>Visit the Science Pavilion</td>
<td>Break</td>
</tr>
<tr>
<td>5:00–6:00 pm</td>
<td>YIA #1 - Cardiovascular</td>
<td>12:15–12:30 pm</td>
<td>Break</td>
<td>Visit the Exhibit Hall</td>
</tr>
<tr>
<td>6:00–6:15 pm</td>
<td>Break</td>
<td>12:30–1:30 pm</td>
<td>Visit the Exhibit Hall Visit the Science Pavilion</td>
<td>Visit the Exhibit Hall</td>
</tr>
<tr>
<td>6:15–7:15 pm</td>
<td>YIA #2</td>
<td>Lunch Break – Visit the Exhibit Hall Satellite Symposium (two on each day)</td>
<td>Visit the Science Pavilion</td>
<td>Visit the Science Pavilion</td>
</tr>
<tr>
<td>7:15–8:15 pm</td>
<td>SNMMI-TS President’s Town Hall/Reception</td>
<td>2:30–3:30 pm</td>
<td>Current Perspective on Total Body PET and Applications</td>
<td>Visit the Science Pavilion</td>
</tr>
<tr>
<td>8:15–10:15 pm</td>
<td>Movie Night</td>
<td>3:30–4:30 pm</td>
<td>Pearls and Pitfalls in PET: DOTATATE, Amyloid, Fluiclovine, PSMA</td>
<td>On the Horizon: Developing Techniques, New Isotopes and Production Chemistry</td>
</tr>
<tr>
<td>9:00–10:00 am</td>
<td>Molecular Hub – Early Career Professionals</td>
<td>4:30–5:00 pm</td>
<td>Visit the Exhibit Hall</td>
<td>3:30–4:30 pm</td>
</tr>
<tr>
<td>10:00–11:00 am</td>
<td>SNMMI Business Meeting/Cassen Lecture</td>
<td>5:00–6:00 pm</td>
<td>Visit the Exhibit Hall</td>
<td>New Imaging Boot Camp: FES, 18F-DOPA, New Net Imaging Agents, FAPI</td>
</tr>
<tr>
<td>11:00–11:15 am</td>
<td>Special Session – Nuclear Medicine in the Time of COVID-19</td>
<td>YIA #5</td>
<td>Visit the Exhibit Hall</td>
<td>1:30–2:30 pm</td>
</tr>
<tr>
<td>11:15 am–12:15 pm</td>
<td>Theranostics - How to Do Radiation Safety Right?</td>
<td>12:30–1:30 pm</td>
<td>Visit the Exhibit Hall – Satellite Symposium (two on each day)</td>
<td>Lunch Break – Visit the Exhibit Hall – Satellite Symposium (two on each day)</td>
</tr>
<tr>
<td>12:15–12:30 pm</td>
<td>Break</td>
<td>2:30–3:30 pm</td>
<td>On the Horizon: Developing Techniques, New Isotopes and Production Chemistry</td>
<td>2:30–3:30 pm</td>
</tr>
<tr>
<td>12:30–1:30 pm</td>
<td>Visit the Exhibit Hall Visit the Science Pavilion</td>
<td>3:30–4:30 pm</td>
<td>Prostate Cancer Theranostics- Applications of Molecular Targeted Radiotherapy</td>
<td>3:30–4:30 pm</td>
</tr>
<tr>
<td>12:30–1:30 pm</td>
<td>Visit the Exhibit Hall Visit the Science Pavilion</td>
<td>4:30–5:00 pm</td>
<td>Visit the Exhibit Hall</td>
<td>4:30–5:00 pm</td>
</tr>
<tr>
<td>1:30–2:30 pm</td>
<td>Lunch Break – Visit the Exhibit Hall – Satellite Symposium (two on each day)</td>
<td>5:00–6:00 pm</td>
<td>Visit the Exhibit Hall</td>
<td>Visit the Exhibit Hall</td>
</tr>
<tr>
<td>2:30–3:30 pm</td>
<td>CE Session</td>
<td>YIA #3</td>
<td>YIA #6</td>
<td>Visit the Science Pavilion</td>
</tr>
<tr>
<td>3:30–4:30 pm</td>
<td>Scientific Session</td>
<td>6:00–6:15 pm</td>
<td>Break</td>
<td>6:00–6:15 pm</td>
</tr>
<tr>
<td>3:30–4:30 pm</td>
<td>Scientific Session</td>
<td>6:15–7:15 pm</td>
<td>BSS Session #2</td>
<td>Break</td>
</tr>
<tr>
<td>4:30–5:00 pm</td>
<td>Networking Event</td>
<td>7:15–8:15 pm</td>
<td>SNMMI President’s Town Hall/ Reunion</td>
<td>Visit the Science Pavilion</td>
</tr>
<tr>
<td>4:30–5:00 pm</td>
<td>Break</td>
<td>8:15–9:15 pm</td>
<td>Drink &amp; Think</td>
<td>6:15–8:00 pm</td>
</tr>
<tr>
<td>5:00–6:00 pm</td>
<td>Visit the Exhibit Hall</td>
<td>8:00–9:00 pm</td>
<td>Knowledge Bowl</td>
<td>Highlights Lecture</td>
</tr>
<tr>
<td>5:00–6:00 pm</td>
<td>Visit the Science Pavilion</td>
<td>8:00–9:00 pm</td>
<td>Knowledge Bowl</td>
<td></td>
</tr>
<tr>
<td>6:15–7:15 pm</td>
<td>BSS Session #1</td>
<td>8:00–9:00 pm</td>
<td>Knowledge Bowl</td>
<td></td>
</tr>
<tr>
<td>7:15–8:15 pm</td>
<td>YIA #4 – Brain Imaging</td>
<td>8:00–9:00 pm</td>
<td>Knowledge Bowl</td>
<td></td>
</tr>
<tr>
<td>8:15 – 9:15 pm</td>
<td>Drink &amp; Think</td>
<td>8:00–9:00 pm</td>
<td>Knowledge Bowl</td>
<td></td>
</tr>
</tbody>
</table>
CE SESSIONS

The SNMMI 2020 Annual Meeting—Virtual Edition features state-of-the-art, interactive CE Sessions over 3.5 days. These sessions will be one-hour in length and will include live chat functionality to converse with speakers during their presentations.

▶ **CE01: Non-Invasive Evaluation of CAD in 2020**

*Saturday, July 11 ▶ 3:30–4:30 pm*

Organized by the Cardiovascular Council

1. Optimizing SPECT MPI for the COVID19 Era — Randall Thompson, MD
2. PET is the Future of Nuclear Cardiology — Marcelo Di Carli, MD
3. Changing Guidelines and their Impact on Nuclear Cardiology — Rory Hachamovitch, MD
4. Competing Approaches to CAD Evaluation - CT-FFR, Stress CMR and Beyond — Mouaz Husayn Al-Mallah, MD

▶ **CE02: Complementary Roles of Nuclear Medicine and Radiologic Imaging in the Evaluation of Musculoskeletal Diseases**

*Sunday, July 12 ▶ 11:15 am–12:15 pm*

Organized by the General Clinical Nuclear Medicine Council

1. Optimizing SPECT MPI for the COVID19 — Meera Raghavan, MD

▶ **CE03: Lymphoscintigraphy: Review of Basics, Use with SPECT/CT, and Viewpoint of a Surgeon**

*Sunday, July 12 ▶ 12:30–1:30 pm*

Organized by the Correlative Imaging Council

1. A Review of the Basics of Lymphoscintigraphy — Andrew Kozlov, MD
2. Case-Based: How SPECT/CT Contributes to Sentinel Node Detection— Lizette Louw, MD
3. Viewpoint from a Surgeon: How Nuclear Medicine is Utilized for Sentinel Node Detection — Steven D Jones, MD, MPH

▶ **CE04: SPECT/CT Applications in Pediatrics**

*Sunday, July 12 ▶ 2:30–3:30 pm*

Organized by the Pediatric Imaging Council

1. Endocrine — Adina Alazraki, MD
2. Pulmonary — J. Christopher Davis, MD
3. Neuroblastoma: MIBG SPECT/CT — Susan E. Sharp, MD

▶ **CE05: Fundamentals of Brain SPECT/PET Scan Interpretation in Dementia**

*Sunday, July 12 ▶ 3:30–4:30 pm*

Organized by the Brain Imaging Council

1. How to Read and Interpret a Perfusion SPECT/FDG PET Scan— Jonathan McConathy, MD, PhD
2. How to Read and Interpret an Amyloid and Tau PET Scan— Alexander E. Drzezga, MD

▶ **Special Session – Nuclear Medicine in the Time of Covid-19**

*Monday, July 13 ▶ 9:00–10:00 am*

Organized by the SNMMI COVID-19 Taskforce

1. The COVID-19 Pandemic: A Resident’s Perspective — Anthony Hafez, DO
2. The COVID-19 Pandemic: A Technologist’s Viewpoint — Maria C. DaCosta, CNMT
3. The COVID-19 Pandemic: A Faculty’s Perspective — Munir Ghesani, MD, FACNM, FACR
CE SESSIONS
The SNMMI 2020 Annual Meeting—Virtual Edition features state-of-the-art, interactive CE Sessions over 3.5 days. These sessions will be one-hour in length and will include live chat functionality to converse with speakers during their presentations.

► CE06: Theranostics — How to do Radiation Safety Right?
  Monday, July 13 ▶ 11:15 am–12:15 pm
  Organized by the Quality and Evidence Committee
  1. Patient Release after 131-I Therapy (Nal and MIBG) — Frederick D. Grant, MD
  2. Safe use of 223-Ra, 90-Y and 177-Lu Labeled Agents — Michael Sheetz, MS, CHP, DABMP
  3. Promoting Radiation Safety through SAFRON — Debbie Gilley

► CE07: Best Practices to Support the Quality Control of PET Drugs
  Monday, July 13 ▶ 12:30–1:30 pm
  Organized by the Radiopharmaceutical Sciences Council
  1. General Regulations and Requirements— Sally Schwarz, MS, RPh, BCNP, FAPhA
  2. Best Practices of QC for PET Drugs — Denise Jeffers, RPh, ANP
  3. Field Notes — Common Issues and Pitfalls in QC — Amy Vavere, PhD

► CE08: Current Perspective on Total Body PET and Applications
  Monday, July 13 ▶ 2:30–3:30 pm
  Organized by the Physics, Instrumentation, and Data Sciences Council
  1. Design Considerations for a Whole-Body PET Imager: Is there an optimal axial length? — Joel S. Karp, PhD
  2. One year in the use of Explorer: What have we learned? — Ramsey Badawi, PhD
  3. Clinical and Research Opportunities of Total Body PET at University of Pennsylvania — Austin R. Pantel, MD
  4. Dynamic Whole-Body PET and Parametric Imaging — Nicolas A. Karakatsanis, PhD

► CE09: Pearls and Pitfalls in PET: DOTATATE, Amyloid, Fluciclovine, PSMA
  Monday, July 13 ▶ 3:30–4:30 pm
  Organized by the PET Center of Excellence
  1. Pearls and Pitfalls: $^{68}$Ga DOTATATE — Kalpa Prasad, MD
  2. Pearls and Pitfalls: Amyloid PET — Twyla Bartel, DO
  3. Pearls and Pitfalls: Fluciclovine and PSMA — Medhat Osman MD

► TS01: Practical Aspects and Concerns Associated with UPS 825 Implementation
  Tuesday, July 14 ▶ 11:15 am–12:15 pm
  Organized by the SNMMI Technologist Section
  1. History and Development of USP 825 — James Ponto, MS, RPh, BCNP
  2. USP 825 Standard: Implementation into Current Practices — Wendy Galbraith

► CE10: New Imaging Boot Camp: FES, $^{18}$F-DOPA, New NET Imaging Agents, FAPI
  Tuesday, July 14 ▶ 12:30–1:30 pm
  Organized by the Clinical Trials Network
  1. $^{18}$Fluoroestradiol (FES) — Farrokh Dehdashti, MD
  2. $^{18}$F-DOPA - Oncology, Movement Disorder, and CHI — Jonathan McConathy, MD, PhD
  3. New NET Imaging Agents ($^{64}$Cu-dotatoc, $^{68}$Ga-dotatoc) — Andreas Kjaer, MD, PhD
  4. FAPI for Imaging and Therapy — Ken Herrmann, MD
CE SESSIONS

The SNMMI 2020 Annual Meeting—Virtual Edition features state-of-the-art, interactive CE Sessions over 3.5 days. These sessions will be one-hour in length and will include live chat functionality to converse with speakers during their presentations.

▶ CE11: On the Horizon - Developing Techniques, New Isotopes and Production Chemistry
Tuesday, July 14 ▶ 2:30–3:30 pm
Organized by the Center for Molecular Imaging Innovation and Translation (CMIIT)

1. Radiolabeling Comparison of Accelerator Versus Generator Produced Ac-225
   Vanessa A. Sanders, PhD

2. 47Sc- cDTPA-TOC from Harvested Calcium
   E. Paige Abel

3. A Dual Generator Concept to Yield 226Th - An Isotope of Interest for Targeted Alpha Therapy
   Mitchell Friend, MD

4. Production of Theragnostic Radio-Scandium
   Suzanne E. Lapi, PhD

▶ CE12: Prostate Cancer Theranostics - Applications of Molecular Targeted Radiotherapy
Tuesday, July 14 ▶ 3:30–4:30 pm
Organized by the Therapy Center of Excellence

1. Prostate Cancer Osseous Radiotherapy
   Chadwick L. Wright, MD, PhD

2. Alpha Emitting PSMA Radiotheranostics
   Hossein Jadvar, MD, PhD, FACNM, FSNMMI

3. Gastrin-Releasing Peptide Receptor Radiotheranostics
   Andrei Iagaru, MD
SNMMI is pleased to once again Industry Satellite Symposiums during the Annual Meeting. These one-hour sessions provide a forum for our industry partners to directly address the nuclear medicine and molecular imaging community. SNMMI does not endorse any products or services referenced in these symposiums.

**The Role of LUTATHERA® (lutetium Lu 177 dotatate) in Patients With Progressive GEP-NETs**
*Sunday, July 12  ➤  1:30-2:30 pm ET*
*Sponsored by Advanced Accelerator Applications*
*Dr. Eric Liu, MD, FACS (Rocky Mountain Cancer Centers, Denver, Colorado)*

**Estrogen Receptor PET/CT Imaging with a Novel Biomarker: Underlying Biology, Biochemistry and Clinical Application**
*Sunday, July 12  ➤  1:30-2:30 pm ET*
*Sponsored by Siemens*
*David Mankoff, MD, PhD, Gerd Muehllehner Professor of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia*

**PSMA Imaging: Current Status and Prospects**
*Monday, July 13  ➤  1:30-2:30 pm ET*
*Sponsored by Telix Pharmaceuticals*
*Alton O. Sartor MD, Piltz Professor of Cancer Research, Departments of Medicine Hematology/Medical Oncology Tulane Medical Center*
*Jeffery Karnes, MD, Mayo Clinic Rochester, Minn.*
*Jeremie Calais, MD, MSc, Assistant Professor at the Ahmanson Translational Imaging Division of the Dept. of Molecular & Medical Pharmacology*

**Critical Considerations in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)**
*Tuesday, July 14  ➤  1:30-2:30 pm ET*
*Sponsored by Advanced Accelerator Applications*
*Dr Munir Ghesani, MD [Mount Sinai Hospital, New York]; Dr Erin E. Grady, MD [Emory University Hospital, Atlanta, Georgia]*

**Development & Application of Novel PET Tracer for AMPA Receptors**
*Tuesday, July 14  ➤  1:30-2:30 pm ET*
*Sponsored by Eisai*
*Takuya Takahashi, MD, PhD; Professor, Department of Physiology; Yokohama City University Graduate School of Medicine, Japan*
**VIRTUAL EXHIBIT HALL**

Visit customized virtual booths from top suppliers and learn more about their products/services through videos and downloadable presentations. Plus, connect through one-on-one meetings with exhibit personnel while visiting their booth.

**EXHIBITING COMPANIES INCLUDE:**

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABX-CRO advanced pharmaceutical services</td>
<td>Bruker BioSpin</td>
</tr>
<tr>
<td>ACIC - PBL</td>
<td>Canon Medical Systems USA, Inc.</td>
</tr>
<tr>
<td>Actinium Pharmaceuticals</td>
<td>Capintec, Inc. (part of Mirion Technologies)</td>
</tr>
<tr>
<td>Advanced Accelerator Applications, a Novartis Company</td>
<td>Cardinal Health</td>
</tr>
<tr>
<td>Alzheimer's Association</td>
<td>Curium</td>
</tr>
<tr>
<td>American Board of Nuclear Medicine (ABNM)</td>
<td>Cyclomedical International, Inc.</td>
</tr>
<tr>
<td>American College of Nuclear Medicine (ACNM)</td>
<td>Digirad Corporation</td>
</tr>
<tr>
<td>American College of Radiology (ACR)</td>
<td>DOTmed HealthCare Business News</td>
</tr>
<tr>
<td>AnazaoHealth Corporation</td>
<td>ec² Software Solutions</td>
</tr>
<tr>
<td>Applied Nanotech, Inc.</td>
<td>The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF)</td>
</tr>
<tr>
<td>ARRT, The American Registry of Radiologic Technologists</td>
<td>European Association of Nuclear Medicine (EANM)</td>
</tr>
<tr>
<td>Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB)</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>Astellas Pharma US</td>
<td>Hermes Medical Solutions, Inc.</td>
</tr>
<tr>
<td>Bayer Oncology</td>
<td>Huayi Isotopes Company</td>
</tr>
<tr>
<td>Bayer - Radiology</td>
<td>Intersocietal Accreditation Commission (IAC)</td>
</tr>
<tr>
<td>Biodex Medical Systems, Inc.</td>
<td>Ionetix Corporation</td>
</tr>
<tr>
<td>Blue Earth Diagnostics, Inc.</td>
<td>ITM Isotopen Technologien München AG</td>
</tr>
<tr>
<td>Bracco Diagnostics</td>
<td>Jubilant Radiopharma</td>
</tr>
</tbody>
</table>

*As of June 2, 2020*
# VIRTUAL EXHIBIT HALL

Visit customized virtual booths from top suppliers and learn more about their products/services through videos and downloadable presentations. Plus, connect through one-on-one meetings with exhibit personnel while visiting their booth.

**EXHIBITING COMPANIES INCLUDE:**

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lantheus Medical Imaging, Inc.</td>
<td>Progenics Pharmaceuticals - Medical Affairs</td>
</tr>
<tr>
<td>Life Molecular Imaging</td>
<td>RadioMedix</td>
</tr>
<tr>
<td>Lilly</td>
<td>RI-TE Radiation Imaging Technologies, Lda</td>
</tr>
<tr>
<td>Lucerno Dynamics, LLC</td>
<td>Scoperta Life Sciences</td>
</tr>
<tr>
<td>MarShield Radiation Protection Products</td>
<td>Siemens Healthineers</td>
</tr>
<tr>
<td>MedImage, Inc.</td>
<td>Sirona Complete Care</td>
</tr>
<tr>
<td>MiE America</td>
<td>SHINE Medical Technologies, LLC</td>
</tr>
<tr>
<td>MILabs</td>
<td>South West Exposures</td>
</tr>
<tr>
<td>MIM Software Inc.</td>
<td>Spectrum Dynamics Medical, Inc.</td>
</tr>
<tr>
<td>MOLECUBES NV</td>
<td>Telix Pharmaceuticals</td>
</tr>
<tr>
<td>MR SOLUTIONS</td>
<td>Tema Sinergie</td>
</tr>
<tr>
<td>Northstar Medical Radioisotopes, LLC</td>
<td>Triskem International</td>
</tr>
<tr>
<td>Nuclear Medicine Technology Certification Board (NMTCB)</td>
<td>TTG Imaging Solutions</td>
</tr>
<tr>
<td>NUCMEDCOR</td>
<td>United Imaging</td>
</tr>
<tr>
<td>PETNET Solutions</td>
<td>Universal Medical Resources, Inc.</td>
</tr>
<tr>
<td>Philips</td>
<td>Versant Medical Physics and Radiation Safety</td>
</tr>
<tr>
<td>PMB ALCEN</td>
<td>World Molecular Imaging Society (WMIS)</td>
</tr>
<tr>
<td>PMOD Technologies LLC</td>
<td></td>
</tr>
<tr>
<td>Progenics Pharmaceuticals</td>
<td></td>
</tr>
</tbody>
</table>

*As of June 2, 2020*
NETWORKING EVENTS

Movie Viewing Party
Organized by the Women in Nuclear Medicine Committee (WINM)
Sponsored by Bracco Diagnostics
Saturday, July 11  ▶  beginning at 7:15 pm ET
Join the WINM for a movie viewing party of the popular film: “Radioactive” Plus, be on the lookout for a special announcement!

Molecular Hub
Take a break from the CE sessions and join your colleagues at the Virtual Molecular Hub! Each day will feature a new topic and leaders within the field.

We invite you to begin your SNMMI Virtual Meeting experience on Saturday, July 11 at 1:30 pm. Umar Mahmood, MD, PhD, SNMMI Scientific Program Committee Chair will be providing an overview of the Virtual Meeting platform. Learn how to navigate the meeting, connect with friends and colleagues and visit the exhibit hall.

On Sunday, July 12 at 9:00 am join the Council and Center Leadership as they provide brief overviews of their activities and important information on how to get involved and connect with other individuals in your area of expertise.

Finally, on Tuesday, July 14 at 9:00 am, residents and early career professionals are invited to the Early Career Professionals Committee. Learn from the ECP leaders what resources, how to get involved and provide your feedback on the needs of the early career professional community.

Knowledge Bowl
Tuesday, July 14  ▶  8:00-9:00 pm ET
The SNMMI Early Career Professionals Committee (EPC) is excited to sponsor the Virtual Knowledge Bowl again this year! This event provides an opportunity for residents and early career professionals to network with each other in a competition of the mind! Attendees will be shown difficult general nuclear medicine and PET tracer cases, examine basic science questions and interpret important correlative imaging findings. All of this in a fun, interactive virtual platform.
Drink and Think
Join your colleagues and friends for an informal virtual networking event. Drink and Think is where a virtual happy hour meets an exchange of scientific knowledge and discussion. The Virtual Meeting will feature two days of opportunities to participate in Drink and Think meet-ups which will include topics hosted by SNMMI Councils and Centers. We encourage you to grab a late evening snack, a drink, and be ready to discuss some of the most exciting topics in the field. A list of the schedule topics are included below:

Sunday, July 12  ▶  8:15-9:15 pm ET
- Phased Re-opening Plans for Pediatric Nuclear Radiology Departments – Sponsored by the Pediatric Imaging Council
- New PET Radiopharmaceuticals: Practical Tips? – Sponsored by the PET Center of Excellence
- Artificial Intelligence in Nuclear Medicine – Sponsored by the Physics, Instrumentation and Data Sciences Council
- Prostate Imaging with PSMA PET and How it Plays into Other Imaging Modalities – Sponsored by the Correlative Imaging Council
- Expert Eyes on Details - Deep Cerebellar Nuclei in Neurodegenerative Imaging by Kuhl-Lassen Award Winner, Dr Nicolas Bohnen — Sponsored by the Brain Imaging Council
- How Toxic Environments Affect Productivity — Sponsored by the CMIIIT

Monday, June 13  ▶  8:15-9:15 pm ET
- Total Body PET – Sponsored by the Physics, Instrumentation and Data Sciences Council
- Targeted Radionuclide Therapy for Non-thyroid Pediatric Malignancies: What’s Here and What’s on the Horizon? – Sponsored by the Pediatric Imaging Council
- Nuclear Medicine and COVID-19 – Sponsored by the General Clinical Nuclear Medicine Council
- 21CFR2Beers...Regulatory Considerations for the Radiopharmaceutical Sciences in 2020 – Sponsored by the Radiopharmaceutical Sciences Council
- Nuclear Medicine Practice Optimization – Opportunity for Physician Extenders – Sponsored by the Advanced Associate Council
- Resident Training and Recruitment in the Time of Covid – Sponsored by the Academic Council
- What are You Most Excited About with the Future of Nuclear Medicine Therapies? – Sponsored by the Therapy Center of Excellence
Virtual Hot Trot 5K Run/Walk
Organized by the SNMMI-TS PDEF

The Hot Trot 5K is back this year, in a virtual way. Proceeds will benefit the SNMMI-TS Professional Development and Education Fund, supporting the advancement of molecular and nuclear medicine technologists. All registered runners will receive an official race shirt and medal. Sign up by June 30.

SNMMI-TS President’s Reception
Saturday, July 11, 2020  ➤  7:15 pm ET
Honoring: Mark Crosthwaite, CNMT, FSNMMI-TS — SNMMI-TS President

Join your colleagues on Saturday, July 11 at 7:15 pm ET, as SNMMI honors outgoing SNMMI-TS President Mark Crosthwaite, CNMT, FSNMMI-TS. This informal one-hour virtual town hall and reception will feature brief remarks from Mr. Crosthwaite, as well as a question and answer period for you to interact directly with the outgoing president. Plus, don’t miss The Thallium Stallions, who will debut their new “COVID-19” song at the start of the reception – sponsored by Sirona Complete Care.

SNMMI President’s Reception
Monday, July 13, 2020  ➤  7:15 pm ET
Honoring: Vasken Dilsizian, MD — SNMMI President

Join your colleagues on Monday, July 13 at 7:15 pm ET, as SNMMI honors outgoing SNMMI President Vasken Dilsizian, MD. This informal one-hour virtual town hall and reception will feature live music and brief remarks from Dr. Dilsizian, as well as a question and answer period for you to interact directly with the outgoing president.
### SNMMI 2020 ANNUAL MEETING — VIRTUAL EDITION REGISTRATION

Although registration is required, the Annual Meeting — Virtual Edition is free for SNMMI members. Non-members may either join SNMMI by visiting: www.snmmi.org/AM2020VE to attend at no cost or pay a modest fee.

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Member Rate</th>
<th>Nonmember Rate</th>
<th>JOIN FIRST AND SAVE! CURRENT MEMBERSHIP DUES*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full (Physician/Scientist/Pharmacist)</td>
<td>Free</td>
<td>$299</td>
<td>$199</td>
</tr>
<tr>
<td>Associate (Scientist)</td>
<td>Free</td>
<td>$199</td>
<td>$140</td>
</tr>
<tr>
<td>Affiliate (Industry/Other)</td>
<td>Free</td>
<td>$250</td>
<td>$150</td>
</tr>
<tr>
<td>Technologist/Associate Technologist</td>
<td>Free</td>
<td>$99</td>
<td>$50</td>
</tr>
<tr>
<td>Associate Scientific Laboratory Professional</td>
<td>Free</td>
<td>$199</td>
<td>$140</td>
</tr>
<tr>
<td>Scientific Laboratory Professional</td>
<td>Free</td>
<td>$99</td>
<td>$50</td>
</tr>
<tr>
<td>Emeritus - Physician/Scientist</td>
<td>Free</td>
<td>—</td>
<td>Free</td>
</tr>
<tr>
<td>Emeritus - Technologist</td>
<td>Free</td>
<td>—</td>
<td>Free</td>
</tr>
<tr>
<td>In-Training (All Categories)</td>
<td>Free</td>
<td>—</td>
<td>Free</td>
</tr>
</tbody>
</table>

*Current SNMMI Membership year runs through September 30, 2020. Learn more about [SNMMI Membership categories](www.snmmi.org/AMRegister).

**REGISTRATION CLOSES THURSDAY, JULY 9 AT 11:59 PM ET**
Thank you to our Virtual Edition Sponsors:

▶ TITLE SPONSOR

![Advanced Accelerator Applications](image)

A Novartis Company

▶ GOLD SPONSORS

- Eisai
- MiLabs
- Progenics Pharmaceuticals®
- SIEMENS Healthineers

▶ SILVER SPONSORS

- BRACCO
- CANON
- CURIUM
- HERMES MEDICAL SOLUTIONS
- Lanthanus Medical Imaging

LIFE FROM INSIDE

- Lilly
- mim software
- RadioMedix
- Spectrum Dynamics Medical
- TTg

▶ BRONZE SPONSORS

- Accuitum Pharmaceuticals, Inc.
- astellas
- BAYER
- BIODEX
- BLUE EARTH DIAGNOSTICS
- CAPINTEC, INC.
- Cardinal Health
- ITM
- JUBILANT Radiopharma
- Mediso
- NorthStar Medical Imaging, LLC
- PHILIPS

▶ SATELLITE SYMPOSIUM

- Advanced Accelerator Applications
- Eisai
- GE
- SIEMENS Healthineers

Become a Sponsor
Contact Catherine Lamb at clamb@snmmi.org or Sharon Gleason at sgleason@snmmi.org today.
Diabetes
Primary Hypertension
Hyperthyroidism
Generalized Anxiety Disorder

Is there a deadly pheochromocytoma

Most patients present with the usual suspects—which can lead to misdiagnosis of pheochromocytoma and paraganglioma (PPGL) cases. Delay of accurate diagnosis averages three years. During that time, patients suffer serious symptom burden, and the life-threatening disease can grow.

Patients need your help making PPGL a prime suspect.

Indication
AZEDRA® (iobenguane I 131) is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.

Important Safety Information

Warnings and Precautions:

• Risk from radiation exposure: AZEDRA contributes to a patient’s overall long-term radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. These risks of radiation associated with the use of AZEDRA are greater in pediatric patients than in adults. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with AZEDRA consistent with institutional good radiation safety practices and patient management procedures.

• Myelosuppression: Severe and prolonged myelosuppression occurred during treatment with AZEDRA. Among the 88 patients who received a therapeutic dose of AZEDRA, 33% experienced Grade 4 thrombocytopenia, 16% experienced Grade 4 neutropenia, and 7% experienced Grade 4 anemia. Five percent of patients experienced febrile neutropenia. Monitor blood cell counts weekly for up to 12 weeks or until levels return to baseline or the normal range. Withhold and dose reduce AZEDRA as recommended in the prescribing information based on severity of the cytopenia.

• Secondary myelodysplastic syndrome, leukemia, and other malignancies: Myelodysplastic syndrome (MDS) and acute leukemias were reported in 6.8% of the 88 patients who received a therapeutic dose of AZEDRA. The time to development of MDS or acute leukemia ranged from 12 months to 7 years. Two of the 88 patients developed a non-hematological malignancy.

• Hypothyroidism: Hypothyroidism was reported in 3.4% of the 88 patients who received a therapeutic dose of AZEDRA. Initiate thyroid-blocking medications starting at least 1 day before and continuing for 10 days after each AZEDRA dose to reduce the risk of hypothyroidism or thyroid neoplasia. Evaluate for clinical evidence of hypothyroidism and measure thyroid-stimulating hormone (TSH) levels prior to initiating AZEDRA and annually thereafter.

• Elevations in blood pressure: Eleven percent of the 88 patients who received a therapeutic dose of AZEDRA experienced a worsening of pre-existing hypertension defined as an increase in systolic blood pressure to ≥160 mmHg with an increase of 20 mmHg or an increase in diastolic blood pressure to ≥100 mmHg with an increase of 10 mmHg. All changes in blood pressure occurred within the first 24 hours post infusion. Monitor blood pressure frequently during the first 24 hours after each therapeutic dose of AZEDRA.

• Renal toxicity: Of the 88 patients who received a therapeutic dose of AZEDRA, 7% developed renal failure or acute kidney injury and 22% demonstrated a clinically significant decrease in glomerular filtration rate (GFR) measured at 6 or 12 months. Monitor renal function during and after treatment with AZEDRA. Patients with baseline renal impairment may be at greater risk of toxicity; perform more frequent assessments of renal function in patients with mild or moderate impairment. AZEDRA has not been studied in patients with severe renal impairment.

• Pneumonitis: Fatal pneumonitis occurred 9 weeks after a single dose in one patient in the expanded access program. Monitor patients for signs and symptoms of pneumonitis and treat appropriately.

• Embryo-fetal toxicity: Based on its mechanism of action, AZEDRA can cause fetal harm. Verify pregnancy status in females of reproductive potential prior to initiating AZEDRA. Advise females and males of...
Carcinoid Syndrome
Menopause
Cardiomyopathy
Panic Disorder

lurking in your lineup?

When you spot it, you can treat it.

AZEDRA is the first and only FDA-approved treatment for patients 12 years and older diagnosed with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. Call 1-844-AZEDRA1 to learn more.

reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with AZEDRA and for 7 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the final dose.

• Risk of infertility: Radiation exposure associated with AZEDRA may cause infertility in males and females. Radiation absorbed by testes and ovaries from the recommended cumulative dose of AZEDRA is within the range where temporary or permanent infertility can be expected following external beam radiotherapy.

Adverse Reactions:
The most common severe (Grade 3–4) adverse reactions observed in AZEDRA clinical trials (≥10%) were lymphopenia (78%), neutropenia (59%), thrombocytopenia (50%), fatigue (26%), anemia (24%), increased international normalized ratio (18%), nausea (16%), dizziness (13%), hypertension (11%), and vomiting (10%). Twelve percent of patients discontinued treatment due to adverse reactions (thrombocytopenia, anemia, lymphopenia, nausea and vomiting, multiple hematologic adverse reactions).

Drug Interactions:
Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells and therefore interfere with dosimetry calculations or the efficacy of AZEDRA. These drugs were not permitted in clinical trials that assessed the safety and efficacy of AZEDRA. Discontinue the drugs listed in the prescribing information for at least 5 half-lives before administration of either the dosimetry dose or a therapeutic dose of AZEDRA. Do not administer these drugs until at least 7 days after each AZEDRA dose.

For important risk and use information about AZEDRA, please see Brief Summary of Prescribing Information on adjacent pages.

To report suspected adverse reactions, contact Progenics Pharmaceuticals, Inc. at 844-668-3990 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


AZEDRA® is a registered trademark of Progenics Pharmaceuticals, Inc. All trademarks, registered or otherwise, are the property of their respective owner(s).

© 2019 Progenics Pharmaceuticals, Inc. PM-US-AZ-0260

AZEDRA® is the first and only FDA-approved treatment for patients 12 years and older diagnosed with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. Call 1-844-AZEDRA1 to learn more.
AZEDRA®

ting injection for intravenous use

The following is a Brief Summary; refer to the full Prescribing Information for complete information at www.AZEDRA.com

INDICATIONS AND USAGE
AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iodobenganche scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic therapy.

DOSE AND ADMINISTRATION

Important Safety Information
AZEDRA is a radiopharmaceutical. Handle with appropriate safety measures to minimize radiation exposure. Use waterproof gloves and effective isolation shielding while handling AZEDRA. Radiopharmaceuticals, including AZEDRA, should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals. Verify pregnancy status in females of reproductive potential prior to initiating AZEDRA.

Recommended Dose

Administer thymic blockade and other pre- and concomitant medications as recommended.

Dosimetric Dose

The recommended AZEDRA dosimetric dose administered as an intravenous injection is:

- Patients weighing greater than 50 kg: 182 to 222 MBq (5 or 6 mCi)
- Patients weighing 50 kg or less: 3.7 MBq/kg (0.1 mCi/kg)

Dosimetry and Biostatistical Assessment

Following the AZEDRA dosimetric dose:

- Acquire anterior/posterior whole body gamma camera images within 24 hours of the AZEDRA dosimetric dose and prior to patient voiding (Day 0; Scan 1).
- Acquire additional images on Day 1 or 2 following patient voiding (Scan 2).
- Acquire additional images between Days 2-5 following patient voiding (Scan 3).

For each individual patient, calculate the radiation dose estimates to normal organs and tissues per unit activity [D (organ)] of administered activity [Ãw].

- Minimize radiation exposure to patients, medical personnel, and household contacts of patients.
- Verify pregnancy status in females of reproductive potential to use effective contraception during treatment.
- Verify pregnancy status in females of reproductive potential prior to initiating AZEDRA.

Table 1: Absorbed-dose Threshold Values for Radiation Toxicity in Critical Organs

<table>
<thead>
<tr>
<th>Organ</th>
<th>% 1st-rate mortality</th>
<th>% 1st-rate organ failure</th>
<th>Threshold absorbed-dose for 1st-rate mortality or organ failure (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidneys</td>
<td>&gt;1 year</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>Hepatocellular, ascites</td>
<td>8.5-3 months</td>
<td>31</td>
</tr>
<tr>
<td>Small intestines</td>
<td>duodenal-jejunum</td>
<td>6-8 days</td>
<td>40</td>
</tr>
</tbody>
</table>

- Thresholds of ~0.5 Gy for both heart and carotid artery, derived from experience with external-beam radiotherapy and associated with fractionated exposure, has also been proposed to support an ~1% rate of cardiovascular and cerebrovascular deaths in ~10-15 years. Greater uncertainty is associated with the value in the改正 Gy cited for vascular disease (N Engl J Med, 2012;367;4, Table 4.5), consid3er benefits/risks to patients.

Thyroid Blockade and Other Pre- and Concomitant Medications

- Administer inorganic iodine starting at least 24 hours before and continuing for 10 days after each AZEDRA dose.

- Hydration: Instruct patients to increase fluid intake to at least two liters a day starting at least 1 day before and continuing for 1 week after each AZEDRA dose to minimize irradiation to the bladder.

- Drugs that Reduce Cholecystokinin Uptake or Deplete Stores: Discontinue drugs that reduce cholecystokinin uptake or deplete cholecystokinin stores for at least 5 half-lives before administration of either the dosimetry dose or a therapeutic dose of AZEDRA. Do not administer drug doses until at least 7 days after each AZEDRA dose.

- Antimetics: Administer antimeotics 30 minutes prior to administering each AZEDRA dose.

- Dose Modifications for Adverse Reactions

Recommended dose modifications of AZEDRA for adverse reactions are provided in Table 2 and the recommended dose or dose reduction for the second therapeutic dose of AZEDRA for myelosuppression are provided in Table 3.

Table 2: Recommended Dose Modifications of AZEDRA for Adverse Reactions

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myelosuppression</td>
<td>Do not administer the first therapeutic dose for patients with &lt;1,200/mcL neutrophils, ANC less than 1,200/mcL, or platelets less than 100,000/mcL. Reduce the second therapeutic dose to 425 mCi if the first therapeutic dose was weight based.</td>
</tr>
<tr>
<td>Thyroid Blockade</td>
<td>Do not administer the second therapeutic dose if pneumonitis is diagnosed after the first therapeutic dose.</td>
</tr>
</tbody>
</table>

Table 3: Recommended Dose or Dose Reduction for Second Therapeutic Dose of AZEDRA for Myelosuppression

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>If first therapeutic dose was weight based,</th>
<th>If first therapeutic dose was reduced based on critical organ limits,</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients weighing greater than 62.5 kg</td>
<td>Reduce the second therapeutic dose to 425 mCi.</td>
<td>Reduce the second therapeutic dose to 80% of the first dose.</td>
</tr>
<tr>
<td>Patients weighing 62.5 kg or less</td>
<td>Reduce the second therapeutic dose to 7 mCi/kg.</td>
<td>Reduce the second therapeutic dose to 80% of the first dose.</td>
</tr>
</tbody>
</table>

DOSAGE FORMS AND STRENGTHS

Injection: 335 MBq/15 mL (15 mCi/mL) as a clear, colorless to pale yellow solution in a single-dose vial.

WARNINGS AND PRECAUTIONS

Risk from Radiation Exposure
AZEDRA contributes to a patient’s overall long-term radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. These risks of radiation associated with the use of AZEDRA are greater in pediatric patients than in adults.

- Minimize radiation exposure to patients, medical personnel, and household contacts of patients.
- Reduce radiation exposure to household contacts who are not involved in the treatment.

Myelosuppression
- Severely and potently myelosuppression occurred during treatment with AZEDRA. Among the 88 patients who received a therapeutic dose of AZEDRA, 33% experienced Grade 4 thrombocytopenia, 16% experienced Grade 4 neutropenia, and 7% experienced Grade 4 anemia. Five percent of patients experienced febrile neutropenia. In Study B128 following the first therapeutic dose, patients who experienced Grade 4 neutropenia reached neutrophil nadir at a median of 36 days (27 – 55 days) and remained at nadir for a median of 12 days (8 – 22 days) until recovery to less than or equal Grade 3.

- Monitor blood cell counts weekly for up to 12 weeks or until levels return to baseline or the normal range. Withdraw and dose reduce AZEDRA as recommended based on severity of the cytopenia.

Secondary Myelodysplastic Syndrome, Leukemia and Other Malignancies
Myelodysplastic syndrome (MDS) or acute leukemias were reported in 6.8% of the 88 patients who received a therapeutic dose of AZEDRA. The time to development of MDS or acute leukemia ranged from 12 months to 7 years.

Two of the 88 patients developed a non-hematological malignancy. One patient developed colon cancer at 18 months and one patient developed lung adenocarcinoma at 27 months following the first therapeutic dose.

Hypothyroidism
Hypothyroidism was reported in 3.4% of the 88 patients who received a therapeutic dose of AZEDRA. The incidence of hypothyroidism was 4 months in one patient, and the time to development of hypothyroidism was less than one month in one patient and 18 months in another. The time to hypothyroidism was reaching at least 1 day before and continuing for 10 days after each AZEDRA dose to reduce the risk of hypothyroidism or thyroid neoplasia. Evaluate for clinical evidence of hypothyroidism and measure thyroid-stimulating hormone (TSH) levels prior to initiating AZEDRA and annually thereafter.

Elevations in Blood Pressure
Eleven percent of the 88 patients who received a therapeutic dose of AZEDRA experienced a worsening of pre-existing hypertension defined as an increase in systolic blood pressure to >160 mmHg with an increase of 20 mmHg or increase in diastolic blood pressure to ≥100 mmHg or an increase of 10 mmHg. All changes in blood pressure occurred within the first 24 hours post infusion. Monitor blood pressure frequency during the first 24 hours after each therapeutic dose of AZEDRA.

Renal Toxicity
Of the 88 patients who received a therapeutic dose of AZEDRA, 7% developed renal failure or acute kidney injury and 22% demonstrated a clinically significant increase in glomerular filtration rate (GFR) measured at 6 or 12 months. Monitor renal function during and after treatment with AZEDRA. Patients with baseline renal impairment may be at greater risk of toxicity. Perform more frequent assessments of renal function in patients with mild renal impairment. AZEDRA has not been studied in patients with severe renal impairment (creatinine clearance <30 ml/min).

Pneumonitis
Fetal pneumonitis occurred 9 weeks after a single dose in one patient in the expanded access program for Study B12B (n=11). Pneumonitis was not diagnosed among the 88 patients enrolled in Study B12B or B129. Monitor patients for signs and symptoms of pneumonitis and treat appropriately.

Embryo-Fetal Toxicity
Based on its mechanism of action, AZEDRA can cause fetal harm. There are no available data on the use of AZEDRA in pregnant women. No animal studies using iodobenganche I 131 have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including AZEDRA, have the potential to cause fetal harm.

Verify pregnancy status in females of reproductive potential prior to initiating AZEDRA.

Adverse reactions associated with AZEDRA may cause infertility in males and females. The recommended cumulative dose of 37 Gbq of AZEDRA results in a radiation absorbed dose to the testes and ovaries within the male and female reproductive organs. Adverse reactions associated with AZEDRA can be expected following external beam radiotherapy.

ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Myelosuppression
- Secondary Myelodysplastic Syndrome, Leukemia and Other Malignancies
- Hypothyroidism
- Elevations in Blood Pressure
- Renal Toxicity
- Pneumonitis

Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the clinical trials of another drug and may not reflect the rates observed in practice.

The data in Warnings and Precautions reflect exposure to AZEDRA in 88 patients with iodebenganche-I 131 scan positive recurrent or unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who received a therapeutic dose of AZEDRA in one of two clinical studies (B121 or B122). The Warnings and Precautions also include data from 11 patients enrolled in an expanded access program for Study B12B. The safety data below was evaluated in two studies in patients with recurrent or unresectable, locally advanced or metastatic PPGL. Study
If resulting estimated critical organ absorbed-dose exceeds total of 2 therapeutic doses intravenously a minimum of 90 days apart. (e.g. estimated from imaging).

DOSAGE AND ADMINISTRATION require systemic anticancer therapy. AZEDRA is indicated for the treatment of adult and pediatric patients with malignant or recurrent PPGL. The following is a Brief Summary; refer to the full Prescribing Information (Scan 2).

Adverse reactions from studies IB12 and IB12B are presented in Table 4. The most common severe (Grade 3-4) adverse reactions were lymphopenia (73%), neutropenia (59%), thrombocytopenia (59%), fatigue (26%), anemia (24%), increased international normalized ratio (15%), nausea (15%), dizziness (13%), hypotension (11%) and vomiting (10%). Twelve percent of patients discontinued treatment due to adverse reactions (thrombocytopenia, anemia, neutropenia, nausea and vomiting, multiple hematologic adverse reactions).

**Table 4: Adverse Reactions Occurring in ≥10% of Patients with PPGL Receiving Therapeutic Dose of AZEDRA in Studies IB12B and IB12**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>All Grades</th>
<th>Grades ≥ 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>96</td>
<td>78</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>93</td>
<td>24</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>91</td>
<td>50</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>84</td>
<td>59</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>78</td>
<td>16</td>
</tr>
<tr>
<td>Vomitting</td>
<td>58</td>
<td>10</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>48</td>
<td>2</td>
</tr>
<tr>
<td>Sialadenitis</td>
<td>39</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>23</td>
<td>9</td>
</tr>
<tr>
<td>Constipation</td>
<td>19</td>
<td>7</td>
</tr>
<tr>
<td>Diaphragnic pain</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>General</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>71</td>
<td>26</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>Injection site pain</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Alopecia</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Infections</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>16</td>
<td>2</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>Investigation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>International normalized ratio increased</td>
<td>85</td>
<td>18</td>
</tr>
<tr>
<td>Increased blood alkaline phosphatase</td>
<td>53</td>
<td>5</td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>50</td>
<td>2</td>
</tr>
<tr>
<td>Increased alanine aminotransferase</td>
<td>43</td>
<td>2</td>
</tr>
<tr>
<td>Metabolism and nutrition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>30</td>
<td>5</td>
</tr>
<tr>
<td>Dehydration</td>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>Decreased weight</td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>17</td>
<td>2</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Nervous system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>34</td>
<td>13</td>
</tr>
<tr>
<td>Insomnia</td>
<td>32</td>
<td>6</td>
</tr>
<tr>
<td>Dry eye</td>
<td>24</td>
<td>1</td>
</tr>
<tr>
<td>Respiratory, Thoracic, and mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Vascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>24</td>
<td>4</td>
</tr>
<tr>
<td>Hypertension</td>
<td>20</td>
<td>11</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>10</td>
<td>3</td>
</tr>
</tbody>
</table>

- *NCI CTCAE version 3.0.
- *Based on laboratory data.
- *Includes vomiting and retching.
- *Includes sialoadenitis, salivary gland pain, and salivary gland enlargement.

**Table 4: Adverse Reactions Occurring in ≥10% of Patients with PPGL Receiving Therapeutic Dose of AZEDRA in Studies IB12B and IB12**

**PEDIATRIC USE**

**Pediatric Use**

The safety and effectiveness of AZEDRA have been established in patients 12 years and older with unresectable and iobenguane scan positive, locally advanced or metastatic, pheochromocytoma and paraganglioma (PPGL) which require systemic anticancer therapy. Use of AZEDRA for this indication is supported by evidence from an adequate and well-controlled study in adults and pediatric patients 12 years and older.

The safety and effectiveness of AZEDRA have not been established in pediatric patients younger than 12 years old with unresectable and iobenguane scan positive, locally advanced or metastatic PPGL which require systemic anticancer therapy.

**Geriatic Use**

Of the patients enrolled in all clinical studies of AZEDRA, 17% were 65 years or older and 1% were 75 years or older. Clinical studies of AZEDRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

**Renal Impairment**

The radiation dose to patients with renal impairment may be increased due to the delayed elimination of the drug. Adjust the therapeutic dose based on radiation exposure estimates from the dosimetry assessment. The safety of AZEDRA in patients with severe renal impairment (Clcr < 30 mL/min) or end-stage renal disease has not been studied.

**NONCLINICAL TOXICOLOGY**

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Carcinogenesis, mutagenesis and impairment of fertility studies using iobenguane I 131 have been conducted to evaluate its potential risk for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with AZEDRA and for 80 days after the final dose. Advise patients to take thyroid-blocking agents as prescribed. Advise patients of the need for life-long monitoring for hypothyroidism.

**Efficacy in Blood Pressure**

Advising patients to contact their health care provider for signs or symptoms of hypothyroidism, thrombocytopenia, or anemia. Secondary Myelodysplastic Syndrome, Leukemia and Other Maligancies

Advising patients of the potential for secondary cancers, including myelodysplastic syndrome, acute leukemia, and other malignancies.

**Hypothyroidism**

Advising patients to take thyroid-blocking agents as prescribed. Advise patients of the need for life-long monitoring for hypothyroidism.

**Drug Interactions**

Advising patients to consult their health care provider for signs or symptoms that may occur following tumor-hormone catecholaminelase release and possible risk of increased blood pressure during or 24 hours following each therapeutic AZEDRA dose.

**Pneumonitis**

Advising patients to contact their health care provider for signs or symptoms of pneumonitis. Advise patients of the need for life-long monitoring for hypothyroidism.

**Embryo-Fetal Toxicity**

Advising pregnant women and males of reproductive potential of the potential risk to a fetus. Advise females to inform their health care provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with AZEDRA and for 7 months after the final dose. Advise males of reproductive potential to use effective contraception during treatment with AZEDRA and for 4 months after the final dose.

**Lactation**

Advising females not to breastfeed during treatment with AZEDRA and for 80 days after the final dose. Intermittently

**Advising females and males that AZEDRA may impair fertility.**

**Manufactured for:**

Progenics Pharmaceuticals, Inc.
One World Trade Center, 47th floor, Suite J
New York, NY 10007
AZEDRA® is a registered trademark of Progenics Pharmaceuticals, Inc.
The Hot Trot 5K is back this year, in a virtual way. Proceeds will benefit the SNMMI-TS Professional Development and Education Fund, supporting the advancement of molecular and nuclear medicine technologists. All registered runners will receive an official race shirt and medal. Sign up by June 30.

Learn more at:
www.snmmi.org/HotTrot5k